Germantown, Md., Nov. 18, 2022 (GLOBE NEWSWIRE) — TeraImmune, Inc., a biotechnology company focused on the discovery and development of novel Treg cell therapies for autoimmune diseases, today announced The Data Asia (HCA Asia) 2022 conference, where its TREGable™ technology was showcased at Cell Atlas, was held on November 3-4 in Bangkok, Thailand.
Regulatory T cells (Treg) are a small but important subset of CD4+ T cells that play a role in maintaining immune homeostasis. Through the company-sponsored study, researchers characterized, co-cultured and expanded Treg using 25-mer DNA oligonucleotides, named TREGable™ technology. The identified novel expanded Treg subsets may represent potential clinical therapies for autoimmune diseases. The researchers discovered new eeTregs and demonstrated that such Tregs are fully activated Tregs.
In this study, by comparing single-cell RNA sequencing (scRNA-seq) and ATAC-sequencing between isolated Treg cells and TREGable™-expanded Treg (eTreg) cells, researchers identified a novel Treg (eeTreg), which have high expression of both naive and effector marker genes. A new algorithm to infer master transcription factor (TF) activity in Tregs was also developed to analyze epigenetic signatures using TF ChIP-seq data.These master TFs were more active in eeTregs compared to other Tregs, contributing to their in vitro Expansion period.
“We remain excited to share our highly anticipated Treg expansion technology with the world,” said Dr. Yong Chan Kim, CEO of TeraImmune. “Our advanced TCR/CAR Treg platform includes native Tregs isolated from patients (TREGable™) and Induced Tregs transformed from patient Teff cells (TREGing™) without losing their suppressive activity. The data provide new evidence of the efficacy of TeraImmune’s TREGable/TREGing technology in the stable production of functional Treg cells for cell therapy. We are excited to share our TREGable technology and look forward to preparing a manuscript for publication in a scientific journal. “
On-site poster display details
Title: Simultaneous epigenetic and gene expression profiling of human regulatory T cells at the single-cell level identifies novel effector regulatory T cells
Moderator/Lead Author: Hyun Je Kim, MD, Ph.D., Department of Microbiology and Immunology, Seoul National University College of Medicine
Abstract Number: #20
Session: Technology and Analysis
About HCA Asia
The HCA Asia Conference aims to bring researchers together to share the latest developments and insights, broaden the representation of the Asia-Pacific community, and enhance scientific impact in the region and globally.
About TeraImmune, Inc.
TeraImmune Corporation is a biotechnology company developing innovative immune cell therapies. The company is utilizing a dual Treg manufacturing platform consisting of natural regulatory T cells (Tregs) isolated from the patient (TREGable™) and induced Tregs transformed from the patient’s T effector (Teff) cells (TREGing™) composition. Its Treg platform technology is designed for conditions that suppress adverse immune responses. The company has expanded its pipeline to include allogeneic or off-the-shelf Tregs derived from umbilical cord blood for the treatment of skin conditions such as atopic dermatitis. Selective increase of Tregs with target-specific receptors can suppress unwanted immune responses in patients with autoimmune diseases without side effects.
Westwicke, an ICR company